Cargando…
Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
Autores principales: | Furtado, JJD, Madruga, JV, Bicudo, EL, Eira, M, Lopes, MIB, Netto, EM, de Oliveira, MS, Leite, OHM, Machado, AA, Tupinambas, U, de Andrade Neto, JL, Lima, MPJ, Wajsbrot, DB, Cassoli, LM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112879/ http://dx.doi.org/10.1186/1758-2652-13-S4-P105 |
Ejemplares similares
-
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010) -
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011) -
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014) -
ASP.NET MVC in action: with MvcContrib, NHibernate, and more
por: Palermo, Jeffrey, et al.
Publicado: (2010) -
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)